Form 4: Oncology Institute Director Richard Barasch Acquires Shares and Warrants in Private Placement

Richard Barasch, a director of Oncology Institute, acquired shares and warrants through a private placement, increasing his beneficial ownership.

Summary

• Richard Barasch, a director of Oncology Institute, acquired 1,358,448 shares of common stock and 679,224 common warrants on March 26, 2025, through a private placement.
• The shares were purchased at $1.0417 each, and the warrants at $0.1250 each, as part of a unit offering priced at $2.2084 per unit.
• Following the transaction, Barasch directly owns 1,358,448 shares and indirectly owns 1,775,641 shares through RAB Ventures (DFP) LLC.
• The warrants are exercisable immediately and expire on March 26, 2030, with an exercise price of $1.198.
• The holder may not exercise any portion of a Common Warrant to the extent that the holder would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, which is generally seen as a good sign. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• Director's investment may signal confidence in the company's future prospects.

Risks

• The warrant exercise limitation could restrict potential gains if ownership exceeds 4.99%.

Industry Context

Insider transactions are closely watched as indicators of management's confidence in the company's prospects. A director's purchase can be seen as a positive signal.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The private placement could dilute existing shareholders.

Key Dates

Keywords

Oncology Institute, Richard Barasch, private placement, common stock, common warrant, beneficial ownership, RAB Ventures, director